RZNOMICS
This is a biotechnology company founded by professor Lee Sung-wook's lab They are working on the development of gene therapy products for liver cancer through the development of gene therapy products. It was selected by the TIPS program and was recognized for excellence in technology.
RZNOMICS
Industry:
Biopharma Biotechnology
Founded:
2017-08-01
Address:
Gwangju, Kwangju-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.rznomics.com
Total Employee:
11+
Status:
Active
Contact:
+82 62-974-2905
Total Funding:
59.7 B KRW
Technology used in webpage:
IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Nginx Microsoft Exchange Online Office 365 Mail UNPKG Korea Telecom
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
GE Holdings Japan
GE Holdings is a biotechnology based company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Repertoire Genesis
Repertoire Genesis is a biotechnology company.
Current Employees Featured
Founder
Investors List
Aon plc
Aon plc investment in Series C - Rznomics
SBI Investment Korea
SBI Investment Korea investment in Series C - Rznomics
Quad Ventures
Quad Ventures investment in Series C - Rznomics
Shinhan Venture Investment
Shinhan Venture Investment investment in Series C - Rznomics
IBK Capital
IBK Capital investment in Series C - Rznomics
Partners Investment
Partners Investment investment in Series C - Rznomics
UTC Investment Co.
UTC Investment Co. investment in Series C - Rznomics
Korea Development Bank
Korea Development Bank investment in Series C - Rznomics
Synergy IB Investment
Synergy IB Investment investment in Series B - Rznomics
Partners Investment
Partners Investment investment in Series B - Rznomics
Official Site Inspections
http://www.rznomics.com
- Host name: 183.111.183.33
- IP address: 183.111.183.33
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Rznomics"
Rznomics
About Rznomics. ํ์ ์ RNA ๊ธฐ๋ฐ ๋ฐ์ด์ค ์ ์ฝ ๊ฐ๋ฐ์ ํตํ ์ธ์ฒด์งํ์ ๋ณต ๊ตฌํ์ ์ํด ๊ฐ์/๋ฒ์ฉ ๊ฐ์ข ์/ํดํ์ฑ ์งํ/์ ์ ์งํ์ ๋ํ ์ ์ ์ ์น๋ฃ์ ๊ฐ๋ฐ์ ๋ชฉํ๋ก ํ๊ณ ์์ต๋๋ค.See details»
Rznomics - Crunchbase Company Profile & Funding
Rznomics is located in Gwangju, Kwangju-jikhalsi, South Korea. Who invested in Rznomics? Rznomics has 14 investors including Aon and SBI Investment Korea. How much funding has โฆSee details»
Rznomics Inc. - LinkedIn
Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme.See details»
Rznomics Company Profile 2024: Valuation, Funding
Developer of ribonucleic acid-based gene therapies designed to create new bio drugs for cancer and intractable diseases with highly medical unmet needs.See details»
RZNOMICS Inc. received FDA approval to initiate clinical โฆ
SEONGNAM, South Korea, Oct. 25, 2022 /PRNewswire/ -- Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, โฆSee details»
Charles River and Rznomics Ink RNA-Based Anticancer Gene โฆ
Jan 20, 2023ย ยท Charles River Laboratories International and Rznomics Inc. have announced a viral vector contract development and manufacturing partnership around mRNA-based gene โฆSee details»
Rznomics - Funding, Financials, Valuation & Investors - Crunchbase
Rznomics is a biotechnology company.See details»
Rznomics Company Profile - Office Locations, Competitors ... - Craft
Rznomics is a biotech research company. It is engaged in the development of gene therapy products for liver cancer. Rznomics $10.28 m in total funding,. See insights on Rznomics โฆSee details»
Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ โฆ
Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, has received an Orphan Drug Designation from the U.S. โฆSee details»
Rznomics' RNA-Based Therapy Receives FDA Orphan โฆ
Feb 2, 2024ย ยท The South Korean biopharmaceutical company Rznomics Inc. has announced that its novel RNA-based therapy, RZ-001, designed for the treatment of Hepatocellular Carcinoma (HCC), has been granted Orphan Drug โฆSee details»
Charles River and Rznomics Announce RNA-based ... - Business Wire
Jan 18, 2023ย ยท Rznomics will leverage Charles Riverโs viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.See details»
Rznomics Inc. Secures Fast Track Designation from the U.S. FDA โฆ
Nov 10, 2023ย ยท Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced today that it has received Fast โฆSee details»
Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ โฆ
SEONGNAM, South Korea, Feb. 2, 2024 /PRNewswire/ -- Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, โฆSee details»
SK pharmteco and Rznomics Explore Collaboration for RNA-based โฆ
Rznomics is a South Korea-based innovative RNA biopharmaceutical company with a vision to treat and conquer various human intractable diseases. Rznomics has developed and focused โฆSee details»
RZNOMICS Inc. received FDA approval to initiate clinical โฆ
Oct 25, 2022ย ยท SEONGNAM, South Korea โ Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, โฆSee details»
Charles River and Rznomics Announce RNA-based Anticancer โฆ
Jan 18, 2023ย ยท Charles River Laboratories International, Inc. and Rznomics Inc., a South Korea- based biopharmaceutical company specialized in the development of RNA-based gene โฆSee details»
Charles River and Rznomics Partner on RNA-based Anticancer โฆ
Jan 23, 2023ย ยท Charles River Laboratories and Rznomics, a South Korea-based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, โฆSee details»
Rznomics Inc. Secures Fast Track Designation from the U.S. FDA โฆ
Nov 10, 2023ย ยท As a biopharmaceutical company founded in the laboratory of Professor Seong-Wook Lee, Dankook University Department of Bioconvergence Engineering, Rznomics is โฆSee details»
RZNOMICS Inc. received FDA approval to initiate ... - Pipelinereview
Oct 26, 2022ย ยท Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A โฆSee details»
Rznomics Presents Its Own Circular RNA Platform Technology - PR โฆ
Aug 3, 2023ย ยท Rznomics applied its unique Tetrahymena trans-splicing ribozyme platform technology to effectively convert linear RNA into circular RNA by designing end-to-end self โฆSee details»